ConductScience.org, home

Paper41346702

The efficacy of oligonucleotide-based gene therapeutics in gene silencing.

Patra C and 10 others. Theranostics, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. The efficacy of oligonucleotide-based gene therapeutics in gene silencing. Papers, record 41346702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41346702

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The efficacy of oligonucleotide-based gene therapeutics in gene silencing.
PubMed
Journal
Theranostics
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-08-20
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Patra CChristina
2Hussein ZZain
3Ace VDVeronika D
4Misnik EVElena V
5Rybalko DSDaria S
6Salimova AAAdeliia A
7Ereshko DSDaria S
8Dubovichenko MVMikhail V
9Nour MAYMoustapha A Y
10Drozd VSValeriia S
11Kolpashchikov DMDmitry M

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Genetic TherapyMajor topic
Gene SilencingMajor topic
Oligonucleotides, AntisenseMajor topic
OligonucleotidesMajor topic
Humans
RNA, Small Interfering
Animals

Source PubMed

Download CSV of topics

References229

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120461061Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.Mol Ther2010https://conductscience.org/library/papers/20461061PubMed
232356888Phosphorothioate modified oligonucleotide-protein interactions.Nucleic Acids Res2020https://conductscience.org/library/papers/32356888PubMed
324549300A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent.Mol Ther Nucleic Acids2014https://conductscience.org/library/papers/24549300PubMed
437111328Insights into Exosome Transport through the Blood-Brain Barrier and the Potential Therapeutical Applications in Brain Diseases.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37111328PubMed
538413492Eplontersen: First Approval.Drugs2024https://conductscience.org/library/papers/38413492PubMed
633636127In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.Cell2021https://conductscience.org/library/papers/33636127PubMed
722190188Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration.Cell Tissue Res2012https://conductscience.org/library/papers/22190188PubMed
838609360Engineered, nucleocytoplasmic shuttling Cas13d enables highly efficient cytosolic RNA targeting.Cell Discov2024https://conductscience.org/library/papers/38609360PubMed
936922504Engineered exosomes from different sources for cancer-targeted therapy.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36922504PubMed
1028488596The impact of microfluidic mixing of triblock micelleplexes on in vitro / in vivo gene silencing and intracellular trafficking.Nanotechnology2017https://conductscience.org/library/papers/28488596PubMed
1130846846Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides.Sci Rep2019https://conductscience.org/library/papers/30846846PubMed
1233963053Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome.J Virol2021https://conductscience.org/library/papers/33963053PubMed
1331951854Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties.Mol Ther Nucleic Acids2020https://conductscience.org/library/papers/31951854PubMed
1435221289Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.Drug Metab Dispos2022https://conductscience.org/library/papers/35221289PubMed
1531036929Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.Nat Biotechnol2019https://conductscience.org/library/papers/31036929PubMed
1625614280Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Arterioscler Thromb Vasc Biol2015https://conductscience.org/library/papers/25614280PubMed
1738055260Tominersen in Adults with Manifest Huntington's Disease.N Engl J Med2023https://conductscience.org/library/papers/38055260PubMed
1831863714Impact of Phosphorothioate Chirality on Double-Stranded siRNAs: A Systematic Evaluation of Stereopure siRNA Designs.Chembiochem2020https://conductscience.org/library/papers/31863714PubMed
1931156715The Potential for microRNA Therapeutics and Clinical Research.Front Genet2019https://conductscience.org/library/papers/31156715PubMed
2027001893Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma.J Control Release2016https://conductscience.org/library/papers/27001893PubMed

See all 229 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42673315Tripled-Stranded Antisense Oligonucleotide for Biomarker-Activated Suppression of Essential Genes.Chembiochem2026https://conductscience.org/library/papers/42673315PubMed
42666414Combined Targeted Drug Delivery Systems for Mineral Metabolism Disorders in Chronic Kidney Disease: A Narrative Review.Int J Nanomedicine2026https://conductscience.org/library/papers/42666414PubMed
41752461Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook.Molecules2026https://conductscience.org/library/papers/41752461PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41346702

GET https://conductscience.org/api/papers/v1/41346702/references?page=2